Filing Flows › Marimed (MRMD) › Q1 2026 › vs Q4 2025
Marimed (MRMD) Q1 2026 vs Q4 2025 (quarter over quarter)
Marimed's revenue fell $2.2M (-5%) from $41.6M in Q4 2025 to $39.5M in Q1 2026.
Marimed, Q1 2026: revenue $39.5M (+4% year over year), operating margin 0.3%, net loss $3.8M, operating cash flow $949K. The chart draws each line against Q4 2025, the increases inside each band.
Margins
| Q1 2026 | Q4 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 1.5% | 8.2% | -6.7 pts |
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $39.5M | $41.6M | −$2.2M | -5% |
| Net loss | $3.8M | $4.6M | −$874K | -19% |
| Costs & expenses | $43.2M | $49.0M | −$5.7M | -12% |
| Operating costs | $39.4M | $46.2M | −$6.8M | -15% |
| Interest & other, net | $1.2M | $2.8M | −$1.6M | -56% |
| Income tax | $2.7M | −$2.7M | $5.3M | — |
| Cost of revenue | $24.2M | $31.1M | −$6.9M | -22% |
| Sales & marketing | $765K | $1.2M | −$401K | -34% |
| General & admin | $6.9M | $7.0M | −$70K | -1% |
| Other operating costs | $7.5M | $6.9M | $595K | +9% |
| Operating cash sources | $4.7M | $8.1M | −$3.4M | -42% |
| Depreciation & amortization | $2.2M | $2.1M | $80K | +4% |
| Share-based compensation | $325K | $382K | −$57K | -15% |
| Working capital & other | $2.2M | $5.6M | −$3.4M | -60% |
| Net loss absorbed | $3.8M | $4.6M | −$874K | -19% |
| Operating cash flow | $949K | $3.4M | −$2.5M | -72% |
| Free cash flow (OCF − capex) | $576K | $3.4M | −$2.8M | -83% |
| Capital expenditures | $373K | $33K | $340K | 11× |
Questions
How much did Marimed's revenue grow quarter over quarter in Q1 2026?
Marimed's revenue fell $2.2M (-5%) from $41.6M in Q4 2025 to $39.5M in Q1 2026.